Wald A, Chandra R, Gabel S, Chiponis D
Department of Medicine and Pediatrics, Montefiore Hospital, Pittsburgh, PA 15213.
J Pediatr Gastroenterol Nutr. 1987 Jul-Aug;6(4):554-8. doi: 10.1097/00005176-198707000-00011.
In order to evaluate the efficacy of biofeedback for childhood encopresis, 50 children with encopresis were prospectively studied and randomized to receive biofeedback (B) or mineral oil therapy (M). Specificity of biofeedback was also evaluated by comparing outcomes of both regimens in children with normal (n = 32) and abnormal (n = 18) defecation patterns. Using a single blinded design, there were no significant differences in clinical outcomes between the 24 children receiving B and the 26 children receiving M at 3, 6, and 12 months. However, at 12 months six of nine children with abnormal defecation patterns were in remission or markedly improved after receiving B, compared to only three of nine children receiving M. In contrast, children with normal patterns appeared to respond better to M than did those receiving B (71 vs. 40% at 12 months). Biofeedback appears to warrant further evaluation in children with encopresis and abnormal defecation patterns.
为了评估生物反馈疗法对儿童大便失禁的疗效,我们对50名大便失禁儿童进行了前瞻性研究,并将他们随机分为接受生物反馈疗法(B组)或矿物油疗法(M组)。通过比较排便模式正常(n = 32)和异常(n = 18)的儿童在两种治疗方案下的结果,还评估了生物反馈疗法的特异性。采用单盲设计,在3个月、6个月和12个月时,接受B组治疗的24名儿童与接受M组治疗的26名儿童的临床结果没有显著差异。然而,在12个月时,9名排便模式异常的儿童中,有6名在接受B组治疗后病情缓解或明显改善,而接受M组治疗的9名儿童中只有3名。相比之下,排便模式正常的儿童似乎对M组治疗的反应比对B组治疗的反应更好(12个月时分别为71%和40%)。生物反馈疗法似乎值得在大便失禁且排便模式异常的儿童中进行进一步评估。